Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects?
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
An 80‐year‐old man with multiple comorbidities presented to the emergency department with tachypnea, tachycardia, fever, and critically low O 2 saturation and definitive chest computerized tomography scan findings in favor of COVID‐19 and positive PCR results in 48 hours. He received antiviral treatment plus recombinant human erythropoietin (rhEPO) due to his severe anemia. After 7 days of treatment, he was discharged with miraculous improvement in his symptoms and hemoglobin level. We concluded that rhEPO could attenuate respiratory distress syndrome and confront the severe acute respiratory syndrome coronavirus 2 virus through multiple mechanisms including cytokine modulation, antiapoptotic effects, leukocyte release from bone marrow, and iron redistribution away from the intracellular virus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Viral infection and iron metabolism
Drakesmith, H., & Prentice, A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1930 · Cited by 469
Ganz, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-017-2366-2 · Cited by 270 · cited 1×
“During inflammation, serum Hepcidin levels increase following stimulation by IL-6, downregulating cellular ferroportin and this leads to decreased iron absorption and its detainment in liver and spleen macrophages((12)) which could promote the survival of”
Background
Cited by
COVID-19: Hemoglobin, Iron, and Hypoxia beyond Inflammation. A Narrative Review
Cavezzi, A., Troiani, E., & Corrao, S. (2020) · Clinics and Practice · doi:10.4081/cp.2020.1271 · Cited by 430
Effects of the COVID-19 pandemic on supply and use of blood for transfusion
Stanworth, S. J., New, H. V., Apelseth, T. O., Brunskill, S., Cardigan, R., Doree, C., Germain, M., Goldman, M., Massey, E., Prati, D., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30186-1 · Cited by 338
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich-Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi-Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 338
Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?
Edeas, M., Saleh, J., & Peyssonnaux, C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.05.110 · Cited by 194
“We suggest, in addition to treatment of the inflammatory state (Moore and June, 2020), to envisage the application of approved iron chelators, ferroptosis inhibitors, hepcidin modulators and erythropoietin (Monti et al., 2002; Pinto et al., 2008; Eshagh Hossaini and Haeri, 2019; Bessman et al., 2020; Hadadi et al., 20…”
BackgroundThe Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review
James, P. T., Ali, Z., Armitage, A. E., Bonell, A., Cerami, C., Drakesmith, H., Jobe, M., Jones, K. S., Liew, Z., Moore, S. E., et al. (2021) · The Journal of Nutrition · doi:10.1093/jn/nxab059 · Cited by 147
“Compared with patients with no iron deficiency, having IDA was associated with a longer hospital stay but was not associated with increased mortality, risk of ICU admission, or of mechanical ventilator use.”
BackgroundInfluentialSARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE: COVID-19 and Hematology
Kreidieh, F., & Temraz, S. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.078 · Cited by 7
Metadata
- Authors
- Hadadi, A., Mortezazadeh, M., Kolahdouzan, K., & Alavian, G.
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2020-04-19
- Volume
- 92
- Issue
- 7
- Pages
- 915-918
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- OpenAlex
- W3016053327
- Cited by
- 80
- References
- 2
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.